Yangqing Huang

This inventor holds 8 USPTO granted patents and 3 published patent applications and 9 EPO patents. Top assignees: Brightgene Bio-Medical Technology Co., Ltd., Brightgene Pharmaceutical (Suzhou) Co. Ltd.. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yangqing Huang. Retrieved from https://idiyas.com/inventor/yangqing-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 75.0

EPO Patents = 9 (Patent Applications = 8)

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 13(Granted Patents)

Location History:

Jiangsu, CN (2019 - 2021)
Suzhou, CN (2020 - 2021)

Company Filing History:

8 out of 12

Brightgene Bio-Medical Technology Co., Ltd.

patents

1 out of 1

Brightgene Pharmaceutical (Suzhou) Co. Ltd.

patent

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12215133 - GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use (2025-02-04),

2. 11191843 - Multi-arm targeting anti-cancer conjugate (2021-12-07),

3. 11179467 - Exenatide modifier and use thereof (2021-11-23),

4. 10913756 - Phosphoramidate compound and preparation method and crystal thereof (2021-02-09),

5. 10869863 - Multi-arm polymeric targeting anti-cancer conjugate (2020-12-22),

6. 10689413 - Composition enriched in single isomer of NUC-1031 and preparation method and use thereof (2020-06-23),

7. 10538541 - Phosphoramidate compound and preparation method and crystal thereof (2020-01-21),

8. 10292940 - Hyaluronic acid-based amphiphilic polymer, preparation method and application thereof (2019-05-21),

Title: Yangqing Huang: Innovator in Pharmaceutical Science

Introduction

Yangqing Huang is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceutical science, particularly in the development of innovative therapeutic compounds. With a total of 8 patents to his name, Huang's work focuses on addressing critical health issues such as diabetes and cancer.

Latest Patents

Huang's latest patents include a GIP and GLP-1 dual receptor agonist, which is a pharmaceutical composition designed to reduce blood sugar levels and control body weight. This compound exhibits excellent agonist activity and has promising clinical applications for preventing and treating diabetes and obesity-related complications. Another notable patent is a multi-arm targeting anti-cancer conjugate, which involves a complex drug conjugate that targets specific cancer cells, enhancing the efficacy of treatment.

Career Highlights

Throughout his career, Huang has worked with notable companies such as Brightgene Bio-Medical Technology Co., Ltd. and Brightgene Pharmaceutical (Suzhou) Co. Ltd. His innovative research and development efforts have positioned him as a key player in the pharmaceutical industry.

Collaborations

Huang has collaborated with esteemed colleagues, including Jiandong Yuan and Jianing Gu. These partnerships have furthered his research and contributed to the advancement of pharmaceutical technologies.

Conclusion

Yangqing Huang's contributions to pharmaceutical science through his innovative patents and collaborations highlight his role as a leading inventor in the industry. His work continues to pave the way for new therapeutic solutions that address significant health challenges.

Profile summary based on public USPTO records.